Gastroenterology in 2025 was not shaped by a single breakthrough or defining moment. It was shaped by pressure—rising demand, constrained capacity, shifting economics, and a growing gap between how the system was designed to work and how it actually functions in practice. Across screening, endoscopy, ownership models, site of care, innovation, and workforce sustainability, the specialty spent the year reassessing what still scales, what no longer does, and which assumptions quietly broke along the way. The clearest signal of that reassessment comes from the articles GI leaders returned to most often. The screening model began to fracture under its own…
Author: Abhay Panchal
From seismic policy shifts to blockbuster deals and the accelerating migration of higher-acuity care into the outpatient setting, 2025 was a defining year for the ambulatory surgery center (ASC) industry. ASC News readers gravitated toward stories that captured an industry in transition – one balancing rapid growth and innovation with mounting regulatory action, reimbursement pressures, and questions about scale, ownership and independence. Clinical evolution was another important theme. Readers showed strong interest in how emerging technologies such as surgical robotics are reshaping outpatient care, as well as how operators are rethinking patient selection, cardiovascular services and orthopedic growth to safely…
Remote patient monitoring is steadily reshaping chronic disease care, but its role in inflammatory bowel disease is only now coming into focus. This comprehensive review traces how connected technologies—ranging from home biomarker testing and wearable sensors to passive physiologic monitoring—are being adapted for IBD, drawing lessons from cardiology, endocrinology, and psychiatry. It highlights promising signals around earlier flare detection, patient engagement, and proactive care, while also confronting the unresolved challenges of adherence, regulation, reimbursement, and workflow integration. What emerges is not a finished solution, but a rapidly evolving model of care whose real impact on IBD management is still being…
Physician compensation may look straightforward on paper, but this piece argues that many clinicians enter high-stakes contract negotiations without understanding the very metrics that define their value. Focusing on work relative value units (wRVUs), fair market value, and benchmark data, the authors unpack how hospitals structure pay—and where physicians often lose leverage. As employment models shift and reimbursement pressures grow, the article reframes contract review not as confrontation, but as alignment. Why data literacy has become a career skill for physicians, and how it can materially change outcomes, is explored in this analysis from Healio.
In a large, pragmatic quality improvement program, investigators from the Department of Veterans Affairs showed that the availability of computer-aided detection systems improved adenoma detection rates over those seen at sites where CADe was not provided, although it did not affect all quality colonoscopy indicators. “The odds of adenoma detection improved by 22%. Significant improvements in ADR persisted compared to sites without CADe,” said Jason A. Dominitz, MD, the executive director of the Veterans Health Administration’s National Gastroenterology and Hepatology Program, and a professor of medicine at the University of Washington, in Seattle. However, the researchers also observed a long-term…
CMS released plans Dec. 23 for its voluntary “Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth” — or BALANCE — model. The announcement comes weeks following the White House’s agreements with Eli Lilly and Novo Nordisk to apply most-favored-nation pricing for drugs that treat obesity, diabetes and related conditions. “Today’s announcement builds upon our historic Most Favored Nations drug pricing deals’ goal of democratizing access to weight-loss medication, which has been out of reach for so many in need,” CMS Administrator Mehmet Oz, MD, said in a news release.
New data are challenging a long-held assumption in Crohn’s disease care: that ileal disease is harder to treat than colonic involvement. A post hoc analysis of a phase 3 trial found that subcutaneous infliximab delivered consistent clinical and endoscopic benefits across disease locations—including the terminal ileum—during maintenance therapy. The findings suggest a more uniform treatment effect than many clinicians expect, while also raising questions about how these results will translate outside controlled trials. What surprised investigators most, and what still needs to be proven, is explored in this report from Healio.
Gastroenterology is a highly specialized and rewarding medical field, offering physicians a unique opportunity to blend diagnostic skill with procedural expertise. The demand for skilled GI specialists is consistently high, driven by an aging population, rising rates of digestive diseases, and advancements in screening and treatment. For physicians aiming to build a successful career, understanding the latest clinical trends, technological advancements, and employer expectations is crucial. This guide provides a comprehensive overview of the gastroenterology job market. We will explore the most in-demand subspecialties, the impact of technology on clinical practice, and the essential skills employers are looking for. Whether…
From department chairs and systemwide clinical leaders to national society presidents, gastroenterologists across the country stepped into influential leadership roles in 2025, shaping care delivery, research and professional education. Here are five GI leaders who took on new leadership posts this year: Note: This is not an exhaustive list.
As GLP-1 drugs transform weight loss, a quieter question is gaining urgency: how do patients hold on to those gains once the injections stop? This piece explores a new class of minimally invasive, gut-targeting devices designed to stabilize metabolism after drug-induced weight loss—without weekly shots or lifelong therapy. Early trial results are closely watched, skepticism remains, and multiple approaches are racing toward clinical validation. Whether these one-time procedures represent a durable next chapter in obesity care is becoming one of the most consequential debates heading into 2026, with Fractyl Health emerging as an early contender.